Which GLP-1 Is the Safest? How Approved Weight-Loss Medications Compare on Safety

“Which GLP-1 is the safest?” is one of the most common questions people type before they talk to a doctor about weight-loss medicine. It is a smart question. It just does not have the one-word answer many people hope for.

This guide explains what the FDA labels and the major trials actually say about the safety of approved GLP-1 weight-loss medicines, where they genuinely differ, and why the biggest safety gap is not between brands at all. It is general education, not medical advice. Only a licensed clinician who knows your history can say which medicine, if any, is right for you.

The short answer

There is no single “safest GLP-1.” Every FDA-approved GLP-1 medicine for weight management shares the same core set of warnings, and the side effects people notice most are digestive, dose-related and usually worst while the dose is being raised.

What does differ:

• How often people stopped because of side effects in the main trials: about 7% for Wegovy injection, 5% to 7% for Zepbound, 8% for Foundayo and 10% for Saxenda, versus 3% to 4% on placebo (figures from each label).
• Track record: liraglutide has been used the longest; the pills are the newest.
• Outcome data: Wegovy is the only weight-management GLP-1 approved to lower the risk of heart attack, stroke and cardiovascular death in adults with established heart disease.
• Product quality: FDA-approved medicines are reviewed for safety, effectiveness and manufacturing quality. Compounded, counterfeit and “research-only” products are not, and that is where FDA has documented the most avoidable harm.

So the safest GLP-1 is really an FDA-approved medicine, matched to your health history, started at a low dose and supervised by a licensed clinician.

What “safe” means for a weight-loss medicine

When doctors talk about a medicine’s safety, they usually weigh several different things:

1. Serious but rare risks, such as pancreatitis or severe allergic reactions.
2. Common, bothersome side effects, such as nausea or constipation, which decide whether people can stay on treatment.
3. Who should never take it (contraindications) and who needs extra caution.
4. Interactions with other medicines.
5. Long-term experience, meaning how many people have used it, for how long, and whether large outcome trials have been done.
6. Product quality: whether what is in the pen or bottle is what the label says.

A medicine can look “safest” on one of these and not on another. That is why rankings you see online are often misleading.

Warnings that apply to every approved GLP-1

The labels for Wegovy, Zepbound, Saxenda and Foundayo overlap heavily. All of them:

• carry a boxed warning about thyroid C-cell tumors. These tumors were seen in rodents; the labels say it is unknown whether the medicines cause them in humans. People with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) should not take them;
• warn about acute pancreatitis, with advice to stop the medicine if it is suspected;
• warn about gallbladder disease, including gallstones;
• warn about acute kidney injury, mainly when vomiting or diarrhea leads to dehydration;
• warn about low blood sugar when combined with insulin or sulfonylureas, which may need dose changes;
• warn about serious allergic reactions;
• flag diabetic retinopathy for monitoring in people with type 2 diabetes and existing eye disease; Zepbound’s label also mentions pulmonary aspiration during anesthesia or deep sedation, which is a good reason to tell any surgical team you take a GLP-1, and the Wegovy and Saxenda labels tell clinicians to monitor heart rate. If you have read older advice about suicidal thoughts on GLP-1s, note that FDA has since asked for that warning to be removed from GLP-1 labels; we cover this in who should not take GLP-1s.

In a Brigham and Women’s Hospital training video on prescribing these medicines, an endocrinologist lists the same practical cautions: MTC and MEN 2 as reasons not to use them, pregnancy as a contraindication because of insufficient data, and caution with gallbladder disease, a history of pancreatitis, retinopathy, gastroparesis and use alongside insulin or sulfonylureas.

How the approved options compare on safety

The table below uses figures from each product’s FDA label and its main published trials. Trials differ in length, population and dose schedule, so the numbers are a rough guide, not a ranking.

Medicine (active ingredient)	Form	Stopped due to side effects in label trials (drug vs placebo)	Notable differences
Wegovy (semaglutide)	Weekly injection	6.8% vs 3.2%	Approved to cut major heart events in adults with heart disease; long trial data (SELECT, median ~3.5 years)
Zepbound (tirzepatide)	Weekly injection	4.8% to 6.7% (by dose) vs 3.4%	Dual GIP/GLP-1 agonist; also approved for moderate to severe obstructive sleep apnea with obesity
Saxenda (liraglutide)	Daily injection	9.8% vs 4.3%	Longest US track record; daily dosing
Wegovy pill (oral semaglutide)	Daily tablet	See label	Same ingredient as the injection; strict empty-stomach routine
Foundayo (orforglipron)	Daily tablet	8% (6% to 10% by dose) vs 3%	Non-peptide pill approved in April 2026; newest, with specific drug interactions

A few points help put these numbers in context.

Most people who stopped did so early. The Zepbound label says the majority of people who stopped because of side effects did so in the first few months, mainly because of digestive symptoms. The STEP 1 trial of semaglutide reported that 4.5% stopped because of digestive side effects, compared with 0.8% on placebo, and described nausea and diarrhea as typically mild to moderate and fading over time.

Higher doses bring more side effects. In SURMOUNT-1, side effects led to stopping in 4.3%, 7.1% and 6.2% of people on the 5 mg, 10 mg and 15 mg tirzepatide doses, versus 2.6% on placebo. A 2025 network meta-analysis found the same general pattern across the class: digestive side effects rose with dose, climbing fastest at the lower doses before leveling off.

Serious adverse events were similar. In the SCALE trial of liraglutide 3 mg, serious adverse events occurred in 6.2% of people on the drug and 5.0% on placebo.

For more on the newest options, see orforglipron (Foundayo) explained and oral semaglutide explained.

Semaglutide vs tirzepatide: is one safer?

Semaglutide and tirzepatide are the two medicines people compare most. The best evidence is the head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025. In 751 adults with obesity but without diabetes, tirzepatide led to an average weight loss of 20.2% at 72 weeks, versus 13.7% with semaglutide. In both groups, the most common side effects were digestive, mostly mild to moderate, and occurred mainly during dose increases.

That trial showed tirzepatide works better for weight loss on average. It did not show that either drug is safer overall.

The differences that might matter for an individual are more specific:

• Heart disease: Wegovy’s label includes the SELECT trial, in which 6.5% of people on semaglutide versus 8.0% on placebo had a heart attack, stroke or cardiovascular death over a median of about 3.5 years (hazard ratio 0.80). For someone with established heart disease, that proven benefit can weigh heavily.
• Sleep apnea: Zepbound is approved to treat moderate to severe obstructive sleep apnea in adults with obesity.
• Side-effect pattern: in the 2025 network meta-analysis, semaglutide was the only GLP-1 linked to reflux, and semaglutide and liraglutide (but not tirzepatide) were linked to constipation. These comparisons come largely from separate trials, so they are not definitive.

Our detailed guides on what semaglutide is, what tirzepatide is and semaglutide side effects go further.

Which GLP-1 has the fewest side effects?

The honest answer: the one your body tolerates, at the dose you need.

The 2025 network meta-analysis in the International Journal of Obesity pooled 39 trials with 33,354 people who did not have diabetes. It found that:

• every GLP-1 studied increased the risk of nausea;
• liraglutide, semaglutide, tirzepatide and orforglipron increased vomiting;
• orforglipron (along with exenatide and cagrilintide) was not linked to more diarrhea;
• semaglutide and liraglutide increased constipation;
• semaglutide was the only one significantly linked to reflux (GERD).

The authors suggested that people worried about digestive symptoms might do better with options linked to lower risks in their analysis, while those seeking the most weight loss who can tolerate more side effects may suit injectable semaglutide or tirzepatide. They also noted that the included trials differed a lot from one another, which limits how firmly drugs can be ranked.

Side effects are the main reason people stop, so how they are handled matters as much as which drug you choose. Our guides on GLP-1 nausea, constipation and diarrhea and fiber and hydration on GLP-1s cover the practical side.

Rare but serious risks: how they compare

Pancreatitis and gallbladder problems worry people most. All approved GLP-1s carry warnings for both.

The data on how often they happen are limited because the events are uncommon. In the 2025 network meta-analysis, the trials that reported gallstones and gallbladder inflammation did not show a statistically significant increase for any single drug, and only one trial contributed pancreatitis data. The labels treat both as real risks, and you should know the warning signs: severe, persistent belly pain (sometimes spreading to the back), with or without vomiting, needs urgent medical attention.

Read our deeper guides: GLP-1s and pancreatitis risk and GLP-1 gallbladder problems.

Are GLP-1 pills safer than injections?

Pills appeal to many people because they avoid needles. They are not automatically safer.

• The Wegovy pill contains semaglutide, the same active ingredient as the injection, and carries the same class warnings. It must be taken on an empty stomach with a small amount of water, and its label notes it can raise levels of levothyroxine, a thyroid medicine.
• Foundayo (orforglipron) is a small, non-peptide molecule. In its label, 8% of people stopped because of side effects, compared with 3% on placebo, most often because of digestive effects. In the ATTAIN-1 trial, side effects led to stopping in 5.3% to 10.3% of people on orforglipron versus 2.7% on placebo, and the authors described the side-effect profile as consistent with other GLP-1 medicines.

The main safety trade-off is experience: the pills have been on the market for under a year, compared with more than a decade for liraglutide. For a side-by-side look, see GLP-1 pills vs injections.

The biggest safety gap: approved vs unapproved products

If you take one thing from this article, make it this. The differences between Wegovy, Zepbound, Saxenda and Foundayo are modest. The difference between an FDA-approved product and an unapproved one can be large.

FDA’s page on unapproved GLP-1 drugs lists the problems it has documented:

• Compounded drugs are not FDA-approved. FDA does not review them for safety, effectiveness or quality, and says they should only be used when a patient’s needs cannot be met by an approved drug.
• Adverse event reports: as of May 31, 2026, FDA had received 990 reports linked to compounded semaglutide and more than 730 linked to compounded tirzepatide. It says these are likely underreported, because most state-licensed pharmacies are not required to report them.
• Dosing errors: some hospitalizations may have been linked to people measuring the wrong dose from multi-dose vials, and to clinicians miscalculating doses.
• Doses beyond the label: FDA has received reports tied to compounded products prescribed at higher doses or faster dose increases than the approved labels allow.
• Shipping problems: some compounded injections arrived warm. FDA advises not using any injectable GLP-1 that arrives warm.
• Salt forms: some compounders used semaglutide sodium or acetate, which FDA says are different active ingredients with no known lawful basis for compounding.
• Fraud and counterfeits: FDA is aware of counterfeit Ozempic and of compounded products with fake pharmacy labels.
• “Research-only” products: FDA has warned companies selling semaglutide, tirzepatide, retatrutide and other compounds labeled “for research purposes” or “not for human consumption” for people to inject. Retatrutide is not approved for any use and cannot legally be compounded.

On X, questions like “what’s the safest GLP-1 to take?” sit right next to posts promoting unapproved “peptides” bought online. That mix is exactly why this distinction matters. For a checklist, read red flags for online GLP-1 sellers and our guide to compounded GLP-1 oral solutions and drops.

What about non-GLP-1 weight-loss medicines?

Some people ask whether older weight-loss pills are safer. They have different risks rather than fewer:

Medicine	Key safety points from the label
Contrave (naltrexone/bupropion)	Boxed warning on suicidal thoughts and behaviors; not for people with seizure disorders, uncontrolled high blood pressure, eating disorders such as bulimia or anorexia, or long-term opioid use. 24% stopped due to side effects vs 12% on placebo.
Qsymia (phentermine/topiramate)	Not for use in pregnancy, glaucoma or hyperthyroidism, or with MAO inhibitors.
Xenical (orlistat)	Works in the gut; not for chronic malabsorption, cholestasis or pregnancy. 8.8% stopped due to side effects vs 5.0% on placebo, mostly digestive.

The FDA-approved GLP-1s for weight loss guide explains how these fit alongside the GLP-1 options.

Who should not take any GLP-1

Based on the labels, GLP-1 weight-loss medicines are not for:

• people with a personal or family history of MTC or MEN 2;
• anyone with a known serious allergy to the medicine or its ingredients;
• pregnancy, and labels advise planning ahead if you are trying to conceive.

Extra caution and a careful conversation are needed if you have had pancreatitis, gallbladder disease, severe gastroparesis, diabetic eye disease, kidney problems, or an eating disorder, or if you take insulin or a sulfonylurea. GLP-1s should also not be combined with each other; Wegovy’s label, for example, says not to use it with other semaglutide products or other GLP-1 medicines.

Our full guide to who should not take GLP-1s and the eligibility guide who qualifies for GLP-1 weight loss cover this in detail.

Questions to ask your clinician about safety

Bring these to your appointment, whether it is in person or by telehealth:

1. Given my history, is there any GLP-1 I should avoid?
2. Do my other medicines (for example, insulin, a sulfonylurea, levothyroxine or birth-control pills) need adjusting?
3. Which product has the strongest evidence for my situation, such as heart disease or sleep apnea?
4. How will we raise the dose, and what should I do if side effects are hard to manage?
5. Which symptoms mean I should stop and call you, or go to urgent care?
6. Is this an FDA-approved product, and which licensed pharmacy will fill it?
7. What is the plan for protecting muscle and nutrition? (See how much protein you need on a GLP-1 and strength training on GLP-1s.)

Symptoms that need prompt medical attention

Whatever GLP-1 you take, the labels tell people to seek medical help for:

• severe stomach pain that will not go away, with or without vomiting, which could signal pancreatitis;
• pain in the upper right belly, fever, yellowing of the skin or eyes, or clay-colored stools, which could signal gallbladder problems;
• vomiting or diarrhea that leaves you unable to keep fluids down, because dehydration can harm the kidneys;
• swelling of the face, lips, tongue or throat, or trouble breathing, which could be a serious allergic reaction;
• a lump or swelling in the neck, hoarseness, or trouble swallowing;
• shakiness, sweating, confusion or fast heartbeat if you also take insulin or a sulfonylurea, which could mean low blood sugar.

The bottom line

There is no universally “safest GLP-1.” The FDA-approved options share the same core warnings and mostly digestive, dose-related side effects. They differ modestly in how often people stopped treatment in trials, in how long they have been used, and in specific benefits such as Wegovy’s proven reduction in heart events or Zepbound’s sleep apnea approval. The larger safety difference is between approved medicines from licensed pharmacies and unapproved, compounded, counterfeit or “research-only” products.

The safest path is an FDA-approved medicine, chosen with a licensed clinician who knows your history, started low and raised slowly. Explore more in our GLP-1 Guide hub, starting with what a GLP-1 medication is and how GLP-1s work for weight loss.

Medical disclaimer: This article is for general education and is not medical advice. It does not recommend any specific medicine or dose. Talk with a licensed clinician before starting, stopping or changing any medicine, and follow the prescribing information for your product.